OTCMKTS:HKMPF - Hikma Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$20.82
+0.30 (1.20%)

This chart shows the closing price for HKMPF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hikma Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HKMPF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HKMPF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $20.82.

This chart shows the closing price for HKMPF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Hikma Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/6/2022Morgan StanleyLower Price TargetGBX 2,300 ➝ GBX 2,100
3/3/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight
3/2/2022JPMorgan Chase & Co.Lower Price TargetGBX 3,000 ➝ GBX 2,900
1/20/2022Peel HuntUpgradeHold ➝ Buy
10/19/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight
9/2/2021BarclaysReiterated RatingOverweight
8/20/2021JPMorgan Chase & Co.Reiterated RatingOverweight
8/9/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight
7/1/2021CitigroupReiterated RatingBuy
4/6/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight
3/31/2021Jefferies Financial GroupUpgradeHold ➝ Buy
3/8/2021BarclaysReiterated RatingOverweight
2/26/2021JPMorgan Chase & Co.Reiterated RatingOverweight
2/26/2021Morgan StanleyReiterated RatingEqual Weight
2/18/2021Morgan StanleyReiterated RatingEqual Weight
1/25/2021Peel HuntDowngradeBuy ➝ Hold
11/24/2020JPMorgan Chase & Co.Reiterated RatingOverweight
9/22/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight
9/8/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy
9/4/2020BarclaysUpgradeEqual Weight ➝ Overweight
8/14/2020BarclaysReiterated RatingEqual Weight
7/7/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight
4/28/2020BarclaysReiterated RatingEqual Weight
4/23/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral
4/16/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
3/10/2020CitigroupUpgradeNeutral ➝ Buy
9/3/2019The Goldman Sachs GroupInitiated CoverageBuy
3/19/2019CitigroupUpgradeNeutral ➝ Buy
11/27/2018Jefferies Financial GroupUpgradeHold ➝ Buy
1/10/2018Jefferies Financial GroupDowngradeHold ➝ Underperform
8/22/2017The Goldman Sachs GroupDowngradeBuy ➝ Neutral
8/21/2017Jefferies Financial GroupUpgradeUnderperform ➝ Hold
8/8/2017Morgan StanleyReiterated RatingEqual Weight
8/2/2017Morgan StanleyReiterated RatingOverweight ➝ Equal Weight
(Data available from 5/25/2017 forward)

News Sentiment Rating

-0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/26/2022
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/25/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Hikma Pharmaceuticals logo
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Read More

Today's Range

Now: $20.82
Low: $20.82
High: $20.82

50 Day Range

MA: $25.55
Low: $20.82
High: $28.00

52 Week Range

Now: $20.82
Low: $20.82
High: $37.70

Volume

N/A

Average Volume

600 shs

Market Capitalization

$5.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Hikma Pharmaceuticals?

The following equities research analysts have issued research reports on Hikma Pharmaceuticals in the last year: Barclays PLC, Citigroup Inc., JPMorgan Chase & Co., Morgan Stanley, Peel Hunt, and Zacks Investment Research.
View the latest analyst ratings for HKMPF.

What is the current price target for Hikma Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Hikma Pharmaceuticals in the last year.
View the latest price targets for HKMPF.

What is the current consensus analyst rating for Hikma Pharmaceuticals?

Hikma Pharmaceuticals currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HKMPF will outperform the market and that investors should add to their positions of Hikma Pharmaceuticals.
View the latest ratings for HKMPF.

How do I contact Hikma Pharmaceuticals' investor relations team?

Hikma Pharmaceuticals' physical mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The company's listed phone number is 442073992760 and its investor relations email address is [email protected] The official website for Hikma Pharmaceuticals is www.hikma.com. Learn More about contacing Hikma Pharmaceuticals investor relations.